What is the treatment for adamantinoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Adamantinoma

Complete surgical excision with wide margins is the definitive treatment for adamantinoma, as this rare low-grade malignant bone tumor is not responsive to chemotherapy or radiotherapy. 1

Surgical Approach

Primary Treatment Strategy

  • Wide resection is the treatment of choice for all adamantinomas, regardless of grade, as incomplete excision leads to high recurrence rates of approximately 30%. 1

  • Limb-salvage surgery should be performed whenever feasible rather than amputation, with reconstruction using allografts or prosthetic systems. 2, 3

  • The surgical goal is achieving negative margins, as positive or close margins significantly increase local recurrence risk. 2

Reconstruction Options

  • Frozen allograft reconstruction is a well-established option following wide resection, with successful bone union and functional outcomes reported in multiple series. 3

  • Prosthetic reconstruction may be considered, particularly for large defects, though allograft fracture remains a common complication requiring careful patient counseling. 4

  • Total bone replacement (e.g., total tibia allograft) is technically feasible but carries higher fracture risk and may ultimately require conversion to prosthetic systems. 4

Special Considerations by Subtype

Low-Grade (Osteofibrous Dysplasia-Like) Subtype

  • This subtype will recur if not completely resected but has lower metastatic potential. 1

  • Complete excision remains mandatory despite the lower grade. 1

Classic and Other Subtypes

  • Higher-grade subtypes have metastatic potential in 10-20% of cases, typically to the lungs, and may require consideration of systemic therapy in advanced/metastatic settings. 1

  • When higher-grade areas are present in the primary tumor, systemic therapy may be required, though evidence is limited. 1

Critical Management Pitfalls

Inadequate Initial Surgery

  • Curettage or intralesional procedures are inadequate and lead to inevitable local recurrence. 1

  • Even marginal excision carries unacceptably high recurrence rates compared to wide resection. 5

Misdiagnosis Leading to Inappropriate Treatment

  • Adamantinoma is frequently misdiagnosed as other bone lesions, leading to inadequate initial treatment (curettage, cementing) that necessitates subsequent wide resection. 5

  • Histological diagnosis requires expertise, as the epithelial component can be subtle and easily missed. 4, 5

Surveillance Requirements

Follow-Up Protocol

  • Long-term surveillance extending beyond 15-20 years is mandatory, as late recurrences occurring after 15-20 years are well-documented. 1, 2

  • Follow-up should include clinical examination and imaging of the primary site plus chest imaging to detect pulmonary metastases. 1

High-Risk Populations Requiring Intensive Monitoring

  • Male patients have significantly increased risk of local recurrence (P < 0.05) and require more vigilant surveillance. 2

  • Patients over 20 years of age at diagnosis also demonstrate higher recurrence rates. 2

  • Any patient with incomplete initial excision requires lifelong monitoring given the 30% recurrence rate. 1

Role of Adjuvant Therapies

  • Chemotherapy and radiotherapy have no established role in the primary management of adamantinoma, as this tumor is not chemosensitive or radiosensitive. 1

  • For advanced/metastatic disease not amenable to surgical resection, systemic therapy options are investigational and should be considered only in clinical trial settings. 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Treatment of recurrent adamantinoma of the tibia by wide resection: report of three cases.

Journal of the Formosan Medical Association = Taiwan yi zhi, 1993

Research

Adamantinoma of the proximal femur: a case report.

Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association, 2004

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.